𝔖 Bobbio Scriptorium
✦   LIBER   ✦

High incidence of serious side effects of high-dose dexamethasone treatment in patients with epidural spinal cord compression

✍ Scribed by Ketil Heimdal; Henry Hirschberg; Haldor Slettebø; Kjell Watne; Ole Nome


Publisher
Springer US
Year
1992
Tongue
English
Weight
233 KB
Volume
12
Category
Article
ISSN
0167-594X

No coin nor oath required. For personal study only.

✦ Synopsis


Twenty-eight consecutive patients were given high-dose dexamethasone (96 mg i.v. loading dose, decreasing doses to zero in 14 days) and radiotherapy for epidural spinal cord compression due to malignant disease. There were eight events classified as side effects of the dexamethasone treatment. Four of these were considered as serious (one fatal ulcer with haemmorhage, one rectal bleeding and one gastrointestinal perforation from undetermined origins, and one perforation of the sigmoid colon) giving a total rate of serious side effects of 14.3 percent. Due to the high incidence of serious side effects of the high dexamethasone dose, the regimen was abandoned in favor of a standard dexamethasone dose of 16 mg daily reduced to zero in 14 days. There were three events classified as side effects, but none were considered as serious in 38 consecutive patients receiving this dose. The differences both in total number of side effects and number of serious side effects are statistically significant. There was no significant difference in the number of ambulant patients in the group that received the high dexamethasone dose. We conclude that the high dexamethasone dose in our experience gives an unacceptably high incidence of serious side effects and we have therefore abandoned the regimen in favour of a more standard dexamethasone dose.


📜 SIMILAR VOLUMES


Genetic predictors of patient response a
✍ Elliott Semble; Douglas Metcalf; Robert Turner; Carlos Agudelo; Edward Pisko; A. 📂 Article 📅 1982 🏛 John Wiley and Sons 🌐 English ⚖ 462 KB 👁 2 views

## Abstract Clinical, laboratory, genetic, and radiologic studies were evaluated for 18 patients with rheumatoid arthritis who were treated for a mean of 16.6 months with a regimen involving supplementary aspirin and piroxicam, an investigational, nonsteroidal antiinflammatory agent. Although impro

337. Effect of palliative treatment with
✍ J. Skowronek; K. Adamska; T. Piotrowski; G. Zwierzchowski 📂 Article 📅 2003 🏛 Wielkopolskie Centrum Onkologii 🌐 Polish ⚖ 204 KB

odsetek przerw w leczeniu spowodowanych zabu rzeniami w transporcie zr6dta byt stosunkowo duzy, jednak byty to przerwy kr6tkotrwate i szybko usuwane przez personel. Przerwy w leczeniu byty kr6tsze w przypadku obecnosci dobrze wyszkolonego personelu potrafiqcego samodzielnie wyjasnic ich przyczyn~. Z

A randomized, double-blind comparison of
✍ Suzanne H. Stephens; V. Lee Silvey; Richard H. Wheeler 📂 Article 📅 1990 🏛 John Wiley and Sons 🌐 English ⚖ 414 KB 👁 2 views

Thirty-seven patients with advanced incurable malignancies who were receiving their first course of cisplatin (2 90 mg/mz bolus), alone or in combination with other antineoplastic agents, were entered in this randomized, double-blind study to determine the antiemetic efficacy of the addition of high

Cyclophosphamide plus dexamethasone is a
✍ Ulf-Henrik Mellqvist; Stig Lenhoff; Hans E. Johnsen; Martin Hjorth; Erik Holmber 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 153 KB 👁 2 views

## Abstract ## BACKGROUND Today, intensive therapy that includes high‐dose melphalan with autologous stem cell transplantation (ASCT) is considered standard therapy in younger patients with newly diagnosed myeloma. When the current trial was initiated, combined vincristine, doxorubicin, and dexame

Effect of high-dose intravenous immunogl
✍ Boyd M. Koffman; Marinos C. Dalakas 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 52 KB 👁 2 views

The effect of intravenous immunoglobulin (IVIG) on various laboratory values was measured immediately before and after completion of serial monthly infusions of IVIG (2 g/kg) or an equal volume of placebo over 3-12 months, in 46 patients with neuromuscular diseases participating in controlled trials